Injected Medication To Prevent Migraine Also Reduces Comorbid Depression

The injected medication fremanezumab, brand name Ajovy, which is used to prevent migraine headaches in adults, also reduces comorbid depression symptoms, according to a 28-week randomized clinical trial. The trial compared the effectiveness of fremanezumab with a placebo in reducing the average number of monthly migraine days and depressive symptoms. At the start of the trial, each of the 353 participants had migraine and active symptoms of comorbid major depressive disorder.

During the study, those who received the active medication as a monthly injection over 12 weeks had 5.1 fewer migraine days, compared to 2.9 fewer for . . .